tiprankstipranks
Pyxis Oncology announces dosing of first subject in Phase 1 trial of PYX-201
The Fly

Pyxis Oncology announces dosing of first subject in Phase 1 trial of PYX-201

Pyxis Oncology announced dosing of the first subject in a Phase 1 trial of PYX-201. PYX-201 is a novel antibody-drug conjugate, ADC, product candidate licensed from Pfizer targeting extradomain-B, EDB, of fibronectin, a non-internalizing antigen, that is an integral component of the extracellular matrix in tumors. EDB fibronectin is overexpressed in many solid tumors and minimally expressed in most normal adult tissues. The Company anticipates preliminary data from this trial in early 2024. "PYX-201 has the potential to offer a new approach to targeting multiple tumor types via a multipronged mechanism of action that may benefit patients with solid tumors. We expect to see preliminary data from this study, including biomarker results and potential early signs of clinical activity, in early 2024," said Lara Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. "I’m proud of the work done by the Pyxis Oncology team to initiate dosing in our first clinical trial. Dosing is a significant achievement and important milestone that marks the transition of Pyxis Oncology to a clinical-stage company."

Published first on TheFly

See today’s best-performing stocks on TipRanks >>

Read More on PYXS:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles